Table 2 Clinical and histopathological demographics of 165 PCa patients
From: sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients
|  | n = 165 (100 %) |
|---|---|
Age, yrs | 65 (range: 40-88) |
pT-stage | Â |
<3 | 113 (68.5) |
≥3 | 52 (31.5) |
Extracapsular infiltration | 34 (20.6) |
Infiltration of seminal vesicles | 18 (11.0) |
cT-stage | Â |
<3 | 158 (95.8) |
≥3 | 7 (4.2) |
Serum-PSA, ng/ml | 8.1 (1.8-136) |
PSAD, ng/ml/ml | 0.2 (0.1-1.8) |
Abnormal DRE | 65 (39.4) |
Prostate volume, ml | 33 (10-120) |
Gleason Sum (Biopsy) | Â |
≤6 | 86 (52.1) |
7 | 55 (33.3) |
≥8 | 24 (14.5) |
Highest Gleason Pattern (Biopsy) | Â |
3 | 70 (42.4) |
4 | 62 (37.6) |
5 | 14 (8.5) |
Gleason Sum (RPE) | Â |
6 | 27 (16.4) |
7 | 99 (60.0) |
≥8 | 39 (23.6) |
Highest Gleason Pattern (RPE) | Â |
3 | 28 (17.0) |
4 | 104 (63.0) |
5 | 33 (20.0) |
Gleason Sum change | Â |
upgrade | 85 (51.5) |
downgrade | 15 (9.0) |
Clinically significant PCa (Epstein) | 158 (95.8) |
D’Amico Classification |  |
Low risk | 55 (33.3) |
Intermediate risk | 61 (37.0) |
High risk | 49 (29.7) |
N+ | 22 (13.3) |
R+ | 36 (21.8) |
L+ | 29 (17.6) |
V+ | 2 (1.2) |
Pn+ | 106 (64.2) |